TNFRSF8 and Hodgkins lymphoma: Recently, in a phase 3 trial, a combination of brentuximab vedotin (an anti‐CD30 antibody‐drug conjugate) plus standard chemotherapy showed an improvement in the risk of progression, death, or incomplete response in patients with advanced stages of HL during a 2‐year follow‐up.14